...
首页> 外文期刊>European Journal of Cancer Supplements >Novel monoclonal antibodies to C-terminal end of transmembrane prostate androgen-induced protein (TMEPAI) for evaluation of its role in gastric cancer prognosis
【24h】

Novel monoclonal antibodies to C-terminal end of transmembrane prostate androgen-induced protein (TMEPAI) for evaluation of its role in gastric cancer prognosis

机译:跨膜前列腺雄激素诱导蛋白(TMEPAI)C末端的新型单克隆抗体,用于评估其在胃癌预后中的作用

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: Transmembrane prostate androgen-induced protein 1 (TMEPAI) is a membrane protein that has attracted significant attention of many researchers its involvement in TGF-@b signaling pathway which involved in malignant transformation and metastatic tumor progression. We investigated the TMEPAI expression level in gastric adenocarcinomas in comparison to non-tumor mucosa samples and determined its potential prognostic significance. Materials and methods: Fresh and paraffin-embedded gastric adenocarcinoma samples and paired adjacent normal tissues were collected from gastric cancer patients. Evaluation of the PMEPA 1 gene expression was carried out using RT-PCR. For evaluation of TMEPAI protein expression, monoclonal antibodies (mAbs) were developed by using hybridoma techniques. Specificity of prepared monoclonal antibodies against recombinant TMEPAI and evaluation of its expression in the clinical samples using selected mAbs were performed using immunoblotting and immunohistochemistry. Results: We have identified more than two-fold increase in gene expression of PMEPA1 in tumor tissue in 44% of patients. The monoclonal antibodies have shown the capacity to specifically recognize the recombinant TMEPAI in HEK293T cell lysates. We also evaluate the ability of the selected antibodies to recognize the target protein in fixed cells by immunocytochemistry. The evaluation of TMEPAI in adenocarcinoma samples collected from gastric cancer patients revealed decreased protein expression. We have observed pronounced expression of TMEPAI in normal gastric epithelial cells, while tumor cells from gastric adenomas and adenocarcinomas samples were mostly negative for target protein expression. We found that gastric epithelium cells lose the TMEPAI expression concurrent with severe dysplasia. Conclusion: Apparently, the TMEPAI may be a potential biomarker of malignant transformation risk of the stomach epithelium. The presented study was financially supported by Grants from the Russian Fund for Basic Research (14-04-31500) and Tomsk State University Competitiveness Improvement Program.
机译:背景:跨膜前列腺雄激素诱导蛋白1(TMEPAI)是一种膜蛋白,已引起许多研究人员的关注,它参与了TGF-b信号通路,参与了恶性转化和转移性肿瘤的发展。我们调查了与非肿瘤粘膜样品相比胃腺癌中TMEPAI表达水平,并确定了其潜在的预后意义。材料和方法:从胃癌患者中收集新鲜和石蜡包埋的胃腺癌样品以及成对的相邻正常组织。使用RT-PCR对PMEPA 1基因表达进行评估。为了评估TMEPAI蛋白表达,使用杂交瘤技术开发了单克隆抗体(mAb)。使用免疫印迹和免疫组化方法,对制备的针对重组TMEPAI的单克隆抗体进行特异性鉴定,并使用选定的mAb评估其在临床样品中的表达。结果:我们发现在44%的患者中,肿瘤组织中PMEPA1的基因表达增加了两倍以上。单克隆抗体已显示出在HEK293T细胞裂解物中特异性识别重组TMEPAI的能力。我们还通过免疫细胞化学评估所选抗体识别固定细胞中靶蛋白的能力。对胃癌患者采集的腺癌样品中TMEPAI的评估显示蛋白质表达降低。我们已经观察到正常胃上皮细胞中TMEPAI的明显表达,而来自胃腺瘤和腺癌样品的肿瘤细胞大多对目标蛋白表达呈阴性。我们发现,胃上皮细胞在严重不典型增生的同时会丢失TMEPAI表达。结论:显然,TMEPAI可能是胃上皮恶性转化风险的潜在生物标志物。这项研究得到了俄罗斯基础研究基金会(14-04-31500)和托木斯克州立大学竞争力改善计划的资助。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号